Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively

Royalty Pharma plc

2025-FY EPS reported $1.78 revenue$2,378,193,000

Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).
Net cash from operating activities was $827M in Q4 and $2,490M for FY 2025.
Deployed $2.6B in capital on royalty transactions in 2025, including nine new therapies.
Repurchased 37M shares for $1.2B and increased quarterly dividend by 7% to $0.235.
Provided FY 2026 guidance: Portfolio Receipts expected between $3,275M and $3,425M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.